Pfizer will not apply for emergency use authorization of its coronavirus disease 2019 (COVID-19) vaccine until at least mid-November; infectious disease experts warn of a potential third wave of COVID-19; rates of major depression increased among millennials.
This past Friday, Albert Bourla, PhD, CEO of Pfizer, said that the company would not apply for emergency use authorization (EUA) of its vaccine candidate against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), before the third week of November, which would rule out the possibility of a vaccine ready before Election Day on November 3. The New York Times reports that Bourla says that although preliminary numbers could be collected by the end of October on the vaccine’s efficacy, it would still take at least until mid-November to collect safety and manufacturing data.
According to CNBC, infectious disease experts have warned that the dangerously high number of COVID-19 cases currently in the United States could signal a potentially significant third wave as cases may push even higher ahead of the flu season. As of this past Friday, US COVID-19 cases have grown by 5% in 38 states, with the nation now averaging approximately 55,000 new cases every day, marking a 16% increase compared with a week ago.
According to an analysis by the Blue Cross Blue Shield Association (BCBSA), a 12% increase was found in rates of major depression among a cohort of millennials from 2017 to 2018, with increased rates of alcohol use disorder (7%), tobacco use disorder (5%), and substance use disorder (5%) also noted within the time span. Reported by FierceHealthcare, the report additionally detailed the worsening impact of the pandemic on these trends. Based on survey data conducted by the BCBSA in September of this year, 92% of millennials said the pandemic is having a negative effect on their mental health, 34% reported increased alcohol consumption, and 20% reported an increase in smoking.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More